Zura Bio reports third quarter net loss of $20.0 million on $139.0 million cash balance

Reuters11-13

<a href="https://laohu8.com/S/ZURA">Zura Bio</a> reports third quarter net loss of $20.0 million on $139.0 million cash balance

Zura Bio Ltd. reported a net loss of $20.0 million, or $0.21 per share, for the third quarter of 2025, compared to a net loss of $22.9 million, or $0.26 per share, for the same period in 2024. Research and development expenses were $11.9 million, up from $6.0 million in the third quarter of 2024, primarily due to the ongoing Phase 2 clinical trials of tibulizumab. General and administrative expenses were $7.6 million, down from $13.3 million in the prior year, mainly due to a one-time non-cash share-based compensation expense in 2024. As of September 30, 2025, Zura Bio held $139.0 million in cash and cash equivalents, expected to fund operations through 2027. The company continues to advance its Phase 2 clinical trials for tibulizumab in hidradenitis suppurativa and systemic sclerosis, with topline data from these studies expected in the second half of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zura Bio Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251113296574) on November 13, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2583561656?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-13 19:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583561656","market":"nz","top_or_hot":-1,"title":"Zura Bio reports third quarter net loss of $20.0 million on $139.0 million cash balance","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ZURA\">Zura Bio</a> reports third quarter net loss of $20.0 million on $139.0 million cash balance\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Zura Bio Ltd. reported a net loss of $20.0 million, or $0.21 per share, for the third quarter of 2025, compared to a net loss of $22.9 million, or $0.26 per share, for the same period in 2024. Research and development expenses were $11.9 million, up from $6.0 million in the third quarter of 2024, primarily due to the ongoing Phase 2 clinical trials of tibulizumab. General and administrative expenses were $7.6 million, down from $13.3 million in the prior year, mainly due to a one-time non-cash share-based compensation expense in 2024. As of September 30, 2025, Zura Bio held $139.0 million in cash and cash equivalents, expected to fund operations through 2027. The company continues to advance its Phase 2 clinical trials for tibulizumab in hidradenitis suppurativa and systemic sclerosis, with topline data from these studies expected in the second half of 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zura Bio Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251113296574) on November 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zura Bio reports third quarter net loss of $20.0 million on $139.0 million cash balance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZura Bio reports third quarter net loss of $20.0 million on $139.0 million cash balance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-13 19:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ZURA\">Zura Bio</a> reports third quarter net loss of $20.0 million on $139.0 million cash balance\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Zura Bio Ltd. reported a net loss of $20.0 million, or $0.21 per share, for the third quarter of 2025, compared to a net loss of $22.9 million, or $0.26 per share, for the same period in 2024. Research and development expenses were $11.9 million, up from $6.0 million in the third quarter of 2024, primarily due to the ongoing Phase 2 clinical trials of tibulizumab. General and administrative expenses were $7.6 million, down from $13.3 million in the prior year, mainly due to a one-time non-cash share-based compensation expense in 2024. As of September 30, 2025, Zura Bio held $139.0 million in cash and cash equivalents, expected to fund operations through 2027. The company continues to advance its Phase 2 clinical trials for tibulizumab in hidradenitis suppurativa and systemic sclerosis, with topline data from these studies expected in the second half of 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zura Bio Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251113296574) on November 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDLbLCrWN:1","article_id":"2583561656","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583561656","pubTimestamp":1763033432,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Zura Bio Ltd. reported a net loss of $20.0 million, or $0.21 per share, for the third quarter of 2025, compared to a net loss of $22.9 million, or $0.26 per share, for the same period in 2024. Research and development expenses were $11.9 million, up from $6.0 million in the third quarter of 2024, primarily due to the ongoing Phase 2 clinical trials of tibulizumab. General and administrative expenses were $7.6 million, down from $13.3 million in the prior year, mainly due to a one-time non-cash share-based compensation expense in 2024. As of September 30, 2025, Zura Bio held $139.0 million in cash and cash equivalents, expected to fund operations through 2027. The company continues to advance its Phase 2 clinical trials for tibulizumab in hidradenitis suppurativa and systemic sclerosis, with topline data from these studies expected in the second half of 2026.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ZURA":"Zura Bio"},"translate_title":"Zura Bio报告第三季度净亏损2000万美元，现金余额为1.39亿美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ZURA":0.9},"content_text":"Zura Bio reports third quarter net loss of $20.0 million on $139.0 million cash balance\n    \n\n        Zura Bio Ltd. reported a net loss of $20.0 million, or $0.21 per share, for the third quarter of 2025, compared to a net loss of $22.9 million, or $0.26 per share, for the same period in 2024. Research and development expenses were $11.9 million, up from $6.0 million in the third quarter of 2024, primarily due to the ongoing Phase 2 clinical trials of tibulizumab. General and administrative expenses were $7.6 million, down from $13.3 million in the prior year, mainly due to a one-time non-cash share-based compensation expense in 2024. As of September 30, 2025, Zura Bio held $139.0 million in cash and cash equivalents, expected to fund operations through 2027. The company continues to advance its Phase 2 clinical trials for tibulizumab in hidradenitis suppurativa and systemic sclerosis, with topline data from these studies expected in the second half of 2026.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zura Bio Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251113296574) on November 13, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2583561656","isCrawlerRequest":true}